Hormonal
Obesity is associated with increased expression of PPAR-gamma2 mRNA in human adipose tissue, with levels and the PPAR-gamma2/PPAR-gamma1 ratio positively correlating with BMI.
This research highlights that obesity involves a molecular upregulation of PPAR-gamma2, a key driver of fat cell formation. This suggests that the body's molecular machinery actively promotes fat storage in obesity, potentially making weight management biologically challenging. Understanding this mechanism underscores why simple caloric restriction might trigger compensatory molecular responses (like the rebound in PPAR-gamma2 seen during weight maintenance).
Adipose expression of PPAR-gamma2 mRNA was increased in human obesity... There was a strong positive correlation (r = 0.70, P < 0.001) between the ratio of PPAR-gamma2/PPAR-gamma1 and the body mass index of these patients.
Why this rating
Human in vivo study with clear statistical correlation (r=0.70) and biological plausibility, though observational.
Source
Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids.
Antonio Vidal‐Puig et al. · Journal of Clinical Investigation · 1997
DOI 10.1172/jci119424
More from this paper
- A low-calorie diet (800 kcal) induces a transient 25% decrease in adipose PPAR-gamma2 mRNA expression during weight loss, which rebounds to pre-weight-loss levels during weight maintenance.Good
- Insulin and corticosteroids (dexamethasone) act synergistically to induce PPAR-gamma1 and PPAR-gamma2 mRNA expression in isolated human adipocytes.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →